Skip to main content
NeoImmuneTech, Inc. logo

NeoImmuneTech, Inc. — Investor Relations & Filings

Ticker · 950220 ISIN · KR8840140006 LEI · 254900489QR747TPTT13 KO Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2026-06-10 Share Issue/Capital Cha…
Country US United States of America
Listing KO 950220

About NeoImmuneTech, Inc.

https://www.neoimmunetech.com/en

NeoImmuneTech, Inc. is a clinical-stage, T cell-focused biopharmaceutical company dedicated to the development of novel immuno-therapeutics. The company's lead asset is NT-I7 (efineptakin alfa), a long-acting human interleukin-7 (IL-7) fusion protein designed to amplify and reinvigorate T cells. This core technology aims to enhance the immune system's ability to eliminate cancer cells and pathogens. NT-I7 is being developed as a foundational immuno-oncology therapy for use in combination with other cancer treatments, such as checkpoint inhibitors, as well as for applications in infectious diseases. The company's research is focused on leveraging T cell amplification to address a wide range of challenging diseases.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 92% confidence The document is a Korean regulatory disclosure (‘주요사항보고서’) announcing a decision on a paid-in capital increase (유상증자결정) via third‐party allotment. It provides detailed terms of the new share issuance, subscription pricing, allotment rationale, and use of proceeds. This fits the Share Issue/Capital Change category rather than a report on results or management discussion.
2026-06-10 Korean
주권매매거래정지해제 (액면병합 주권 변경상장)
Regulatory Filings Classification · 85% confidence The document is an official Korean exchange announcement regarding the lifting of a trading suspension (“주권매매거래정지해제”) for a specific security. It does not contain financial statements, management commentary, or other substantive report content. Instead, it’s a regulatory notice of market status change. This fits under General Regulatory Filings (RNS) as a miscellaneous regulatory exchange announcement.
2026-06-09 Korean
[기재정정]코스닥시장상장외국법인외부감사인선임ㆍ해임신고서
Regulatory Filings Classification · 85% confidence The document is a Korean regulatory submission (“코스닥시장상장외국법인 외부감사인 선임ㆍ해임 신고서”) notifying the stock exchange of the appointment/dismissal (and contract extension) of an external auditor and a change in the representative. This is a compliance/regulatory announcement rather than an actual audit report or financial statement. There is no specific category for auditor appointment changes, so it falls under the general “Regulatory Filings” category.
2026-06-05 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 93% confidence The document is a Korean “주식등의 대량보유상황보고서” (Large Shareholding Status Report) detailing the number of shares and voting rights held by a major shareholder and its affiliates, changes in holdings, acquisition methods, and purpose of holding. It is a notification/report of significant share ownership changes, corresponding to a Major Shareholding Notification.
2026-06-05 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is titled “분기보고서” covering the period January 1, 2026 to March 31, 2026 (제13기 1분기), filed with the Financial Supervisory Service and Korea Exchange. It contains detailed quarterly financial statements, business overview, R&D activities, contracts and financial tables for the quarter. It is not merely an announcement of a report but the full quarterly interim report itself. Hence it matches the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-15 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 98% confidence The document is a statutory report filed by an officer (reported as an 임원, director) disclosing his shareholdings and recent transactions (acquisitions/disposals) of the company’s securities. This matches the definition of a Director’s Dealing report (insider transaction disclosure), not a broader financial report or announcement. Therefore, the correct classification is DIRS.
2026-05-14 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.